Form 4: Guardant Health Director Tariq Musa Acquires Shares Through Stock Unit Vesting

Sentiment:

SEC Form 4 Filing


Director Tariq Musa of Guardant Health acquired 250 shares of common stock and 250 restricted stock units through vesting on November 15, 2024.

Summary

  • Tariq Musa, a director at Guardant Health, acquired 250 shares of common stock on November 15, 2024.
  • This acquisition was a result of the vesting of 250 restricted stock units.
  • The restricted stock units were part of an award granted on March 6, 2023, which vests over a four-year period.
  • The initial 25% of the award vested on March 15, 2024, with the remaining 75% vesting monthly over the subsequent three years.
  • Following this transaction, Tariq Musa directly owns 4,996 shares of common stock and 6,996 restricted stock units.

Sentiment

Score: 7

Explanation: The document reflects a routine insider transaction, which is generally neutral to positive. The vesting of shares indicates continued alignment of interests between the director and the company.

Positives

  • The vesting of restricted stock units indicates a continued alignment of interests between the director and the company's long-term performance.
  • The acquisition of shares by a director can be seen as a positive sign of confidence in the company's future prospects.

Industry Context

This is a routine filing related to insider transactions and is common for publicly traded companies. It reflects the standard practice of compensating directors with equity that vests over time.

Comparison to Industry Standards

  • Stock-based compensation, including restricted stock units, is a common practice among publicly traded companies, particularly in the technology and healthcare sectors, to align the interests of management and directors with shareholders.
  • The vesting schedule of the restricted stock units, with a four-year vesting period and a one-year cliff, is a typical structure observed in many companies.
  • Companies like Illumina, Exact Sciences, and Myriad Genetics also use similar equity compensation plans for their directors and executives.

Stakeholder Impact

  • The transaction has a minor positive impact on shareholders as it demonstrates the director's continued stake in the company's success.

Key Dates

DateDescription
2023-03-06Date of grant for the restricted stock units.
2023-03-15First vesting date of 25% of the restricted stock units.
2024-11-15Date of the reported transaction where 250 shares and 250 restricted stock units vested.
2024-11-18Date the form was signed.

Keywords

Guardant Health, Tariq Musa, stock acquisition, restricted stock units, vesting, director, insider trading

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.